Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | IMPDH2 | P12268 | 7/20 | 0.55 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 5/20 | 0.48 |
| ▸ | HINT1 | P49773 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15671158 | 0.93 | TGM2 (0.56) | NT5EIMPDH2IMPDH1POLBTAS1R3 | |
| SCHEMBL12939473 | 0.89 | NT5E (0.57) | NT5EIMPDH2IMPDH1POLBTAS1R3 | |
| SCHEMBL15468735 | 0.89 | NT5E (0.57) | NT5EIMPDH2IMPDH1POLBTAS1R3 | |
| SCHEMBL12194800 | 0.89 | NT5E (0.57) | NT5EIMPDH2IMPDH1POLBTAS1R3 | |
| SCHEMBL1577230 | 0.89 | NT5E (0.57) | NT5EIMPDH2IMPDH1POLBTAS1R3 | |
| SCHEMBL10819909 | 0.89 | NT5E (0.57) | NT5EIMPDH2IMPDH1POLBTAS1R3 | |
| SCHEMBL12231404 | 0.88 | NT5E (0.58) | NT5EIMPDH2IMPDH1POLBTAS1R3 | |
| SCHEMBL4409827 | 0.88 | NT5E (0.57) | NT5EIMPDH2IMPDH1POLBTAS1R3 | |
| SCHEMBL29258522 | 0.88 | NT5E (0.57) | NT5EIMPDH2IMPDH1POLBTAS1R3 | |
| SCHEMBL858664 | 0.87 | HPGD (0.54) | NT5EPOLBTGM2HINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007501615-A | — | — | 2007-02-01 | — | — | JP | claimed |
| EP-1654362-A2 | 5'-AND 3'-CAPPED APTAMERS AND USES THEREFOR | EYETECH PHARMACEUTICALS, INC. (US) | 2006-05-10 | — | — | EP | claimed |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | (OSI) EYETECH, INC. | 2005-05-05 | — | — | US | claimed |
| WO-2005014814-A2 | 5’-AND 3’-CAPPED APTAMERS AND USES THEREFOR | (OSI) EYETECH, INC. (US) | 2005-02-17 | — | — | WO | claimed |
| WO-2023169548-A1 | LPA INHIBITOR AND USE THEREOF | 厦门甘宝利生物医药有限公司 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023066236-A1 | AGT INHIBITOR AND USE THEREOF | 厦门甘宝利生物医药有限公司 | 2023-04-27 | — | — | WO | disclosed |
| US-20230013636-A1 | EXOSOMES-BASED THERAPY FOR LIVER FIBROSIS AND OTHER DISEASES WITH FIBROSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-19 | — | — | US | disclosed |
| CN-114703184-A | LPA inhibitor and use thereof | 厦门甘宝利生物医药有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-113862268-A | AGT inhibitors and uses thereof | 厦门甘宝利生物医药有限公司 | 2021-12-31 | — | — | CN | disclosed |
| US-20210252036-A1 | METHODS OF TREATING CANCER BY INHIBITING UBIQUITIN CONJUGATING ENZYME E2 K (UBE2K) | THLIVERIS, ANDREW T. | 2021-08-19 | — | — | US | disclosed |
| EP-3849543-A1 | METHODS OF TREATING CANCER BY INHIBITING UBIQUITIN CONJUGATING ENZYME E2 K (UBE2K) | Berg LLC (US) | 2021-07-21 | — | — | EP | disclosed |
| WO-2021113761-A1 | EXOSOMES-BASED THERAPY FOR LIVER FIBROSIS AND OTHER DISEASES ASSOCIATED WITH FIBROSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2006012468-A2 | DETECTION OF OLIGONULEOTIDES BY DUAL HYBRIDIZATION | (OSI) EYETECH, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050260651-A1 | Enhanced biologically active conjugates | OLDTECH, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050260153-A1 | Facilitation of iontophoresis using charged moieties | OLDTECH, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005110489-A2 | NUCLEIC ACID APTAMERS CONJUGATED TO HIGH MOLECULAR WEIGHT STERIC GROUPS | (OSI) EYETECH, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050096257-A1 | Administering platelet derived growth factor antagonist and endothelial growth factor antagonist | OPHTHOTECH CORPORATION | 2005-05-05 | — | — | US | disclosed |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | (OSI) EYETECH, INC. | 2005-05-05 | — | — | US | disclosed |
| WO-2005020972-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS | (OSI) EYETECH, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005014814-A2 | 5’-AND 3’-CAPPED APTAMERS AND USES THEREFOR | (OSI) EYETECH, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252036-A1 | METHODS OF TREATING CANCER BY INHIBITING UBIQUITIN CONJUGATING ENZYME E2 K (UBE2K) | UBE2G2, UBE2N, UBE2E1 | NT5E 2925/4885IMPDH2 2232/4885IMPDH1 3028/4885 |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | FLT4, TEK, FLT1 | NT5E 18/4885IMPDH2 829/4885IMPDH1 476/4885 |
| US-20050260153-A1 | Facilitation of iontophoresis using charged moieties | ANXA11, SLC7A1, TRPC6 | NT5E 413/4885IMPDH2 2589/4885IMPDH1 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.